Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name CD274 positive
Gene Variant Detail

CD274 positive (unknown)

Relevant Treatment Approaches Atezolizumab Ipilimumab + Nivolumab Pembrolizumab

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive lung non-small cell carcinoma sensitive Pembrolizumab Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase II/III trial (KEYNOTE-010) that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in improved overall survival (10.4 months at 2mg/kg, 12.7 months at 10mg/kg, vs 8.5 months) compared to chemotherapy in previously treated non-small cell lung cancer patients with CD274 (PD-L1) expression in over 1% of tumor cells (PMID: 26712084, PMID: 27026676, PMID: 27718847; NCT01905657). 26712084 27026676 27718847 detail...
CD274 positive ovarian cancer predicted - sensitive JQ1 Preclinical Actionable In a preclinical study, JQ1 suppressed CD274 (PD-L1) expression in human ovarian cancer cell lines in culture, and inhibited CD274 (PD-L1) expression in both immune cells and tumor cells in syngeneic mouse models of ovarian cancer, resulted in cytotoxic T Cell-dependent inhibition of tumor progression (PMID: 27626654). 27626654
CD274 positive gastric adenocarcinoma sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial, Keytruda (pembrolizumab) treatment resulted in partial response in 22% (8/36) of patients with CD274 (PD-L1)-positive gastric or gastroesophageal junction adenocarcinoma (PMID: 27157491). 27157491
CD274 positive gastroesophageal junction adenocarcinoma sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib tiral, Keytruda (pembrolizumab) treatment resulted in partial response in 22% (8/36) of patients with CD274 (PD-L1)-positive gastric and gastroesophageal junction adenocarcinoma (PMID: 27157491). 27157491
CD274 positive glioblastoma conflicting Pembrolizumab Pembrolizumab Phase Ib/II Actionable In a Phase Ib trial, Keytruda (pembrolizumab) treatment resulted in partial response in 4% (1/25), stable disease in 48% (12/25), a median progression free survival of 2.8 months, and a median overall survival of 14.4 months in patients with CD274 (PD-L1) positive, bevacizumab-naive recurrent glioblastoma (Neuro Oncol (2016) 18 (suppl 6): vi25-vi26.). detail...
CD274 positive fibrous histiocytoma sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in 1 complete response and 1 partial response in 3 patients with CD274 (PD-L1)-positive undifferentiated pleomorphic sarcoma (malignant fibrous histiocytoma) (J Clin Oncol 35, no. 15_suppl (May 20, 2017) 11008; NCT02301039). detail...
CD274 positive osteosarcoma sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in 1 partial response in 2 patients with CD274 (PD-L1)-positive osteosarcoma (J Clin Oncol 35, no. 15_suppl (May 20, 2017) 11008; NCT02301039). detail...
CD274 positive lung small cell carcinoma sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 33% (8/24) in patients with lung small cell carcinoma expressing CD274 (PD-L1) in 1% or more of tumor or stromal cells by IHC, including one patient with a complete response and seven patients with a partial response (PMID: 28813164; NCT02054806). 28813164
CD274 positive gastroesophageal junction adenocarcinoma sensitive Pembrolizumab Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-059) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 15.5% (23/148, complete response 3, partial response 20) with a median response duration of 16.3 months in patients with CD274 (PD-L1)-positive (CPS >=1) gastric cancer or gastroesophageal junction adenocarcinoma (PMID: 29543932; NCT02335411). 29543932
CD274 positive transitional cell carcinoma predicted - sensitive Durvalumab Phase Ib/II Actionable In a Phase I/II trial, treatment with Imfinzi (durvalumab) resulted in an overall response rate (ORR) of 17.8% (34/191) in advanced urothelial carcinoma patients with an ORR of 27.6% (27/98) in patients with high PD-L1 (CD274) expression and 5.1% (4/79) in patients with low or negative PD-L1 (CD274), and similar complete response rates between the two groups (PMID: 28817753; NCT01693562). 28817753
CD274 positive ovarian cancer sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 11.5% (3/26, 1 complete response, 2 partial response) and stable disease in 26.9% (7/26) of patients with CD274 (PD-L1)-positive ovarian cancer, with a median progression-free survival of 1.9 months and a median overall survival of 13.8 months (PMID: 29095678, PMID: 30522700; NCT02054806). 29095678 30522700
CD274 positive malignant spindle cell melanoma predicted - sensitive Pembrolizumab Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, PD-1 blockade therapies including Keytruda (pembrolizumab), Opdivo (nivolumab), and BMS-936559 (alone or in combination) resulted in complete response in 32% (19/60), and partial response in 38% (23/60) of malignant spindle cell melanoma patients, whose tumors contained a high percentage of CD274-positive cells (PMID: 29320474). 29320474
CD274 positive malignant spindle cell melanoma predicted - sensitive Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, PD-1 blockade therapies including Keytruda (pembrolizumab), Opdivo (nivolumab), and BMS-936559 (alone or in combination) resulted in complete response in 32% (19/60), and partial response in 38% (23/60) of malignant spindle cell melanoma patients, whose tumors contained a high percentage of CD274-positive cells (PMID: 29320474). 29320474
CD274 positive malignant spindle cell melanoma predicted - sensitive BMS-936559 Clinical Study - Cohort Actionable In a retrospective analysis, PD-1 blockade therapies including Keytruda (pembrolizumab), Opdivo (nivolumab), and BMS-936559 (alone or in combination) resulted in complete response in 32% (19/60), and partial response in 38% (23/60) of malignant spindle cell melanoma patients, whose tumors contained a high percentage of CD274-positive cells (PMID: 29320474). 29320474
CD274 positive lung non-small cell carcinoma sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is in guidelines as first-line therapy for advanced or metastatic non-small cell lung cancer patients with CD274 (PD-L1) expression 1% to 49% and as preferred first-line therapy with CD274 (PD-L1) expression of 50% or more, and negative for actionable molecular biomarkers; and as continued maintenance and subsequent therapy for patients with CD274 (PD-L1) expression of 1% or more (NCCN.org). detail...
CD274 positive esophagus squamous cell carcinoma predicted - sensitive Camrelizumab Phase I Actionable In a Phase I trial, Camrelizumab (SHR-1210) treatment resulted improved objective response rate (46.7%, 7/15 vs 11.1%, 1/9, p>0.05) and disease control rate (66.7%, 10/15 vs 33.3%, 3/9) in patients with CD274 (PD-L1)-positive advanced esophageal squamous cell carcinoma compared to patients with CD274 (PD-L1)-negative tumors (PMID: 29358502; NCT02742935). 29358502
CD274 positive cervical cancer sensitive Pembrolizumab Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase II trial (KEYNOTE-158) that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in an objective response rate of 14.6% (12/82) in patients with CD274 (PD-L1)-positive (CPS >=1) advanced cervical cancer, including 3 with a complete response and 9 with a partial response (PMID: 30943124; NCT02628067). 30943124 detail... detail...
CD274 positive transitional cell carcinoma sensitive Atezolizumab Atezolizumab Phase II Actionable In a Phase II trial (IMvigor210), treatment with Tecentriq (atezolizumab) resulted in an objective response rate (ORR) of 23% (27/119) in cisplatin-ineligible patients with previously untreated, locally advanced or metastatic urothelial cancer, and ORR was 28% (9/32, 4 complete responses, 5 partial responses) in patients with immune cell CD274 (PD-L1) expression greater than or equal to 5% (PMID: 27939400; NCT02108652). 27939400
CD274 positive transitional cell carcinoma sensitive Pembrolizumab Pembrolizumab Phase II Actionable In a Phase II (KEYNOTE-052) trial, Keytruda (pembrolizumab) treatment resulted in objective response in 24% (89/370) of cisplatin-ineligible patients with urothelial cancer, patients with an expression of CD274 (PD-L1) over 10% demonstrated improved response, with an objective response rate of 38% (42/110) (PMID: 28967485; NCT02335424). 28967485
CD274 positive bladder urothelial carcinoma sensitive Pembrolizumab Pembrolizumab Phase II Actionable In a Phase II clinical study (PURE-01), neoadjuvant Keytruda (pembrolizumab) treatment in patients with muscle invasive bladder cancer with CD274 (PD-L1) combined positive scores greater than or equal to 10% resulted in a 54.3% (19/35) complete pathological response at resection compared to a 13.3% (2/15) complete pathological response at resection in patients with CD274 (PD-L1) CPS less than 10% (PMID: 30343614; NCT02736266). 30343614
CD274 positive glioblastoma no benefit Nivolumab Clinical Study - Cohort Actionable In a retrospective analysis, response to Keytruda (pembrolizumab) or Opdivo (nivolumab) therapy was not predicted by RNA expression levels of CD274 (PD-L1) in glioblastoma patients (PMID: 30742119). 30742119
CD274 positive glioblastoma conflicting Pembrolizumab Pembrolizumab Clinical Study - Cohort Actionable In a retrospective analysis, response to Keytruda (pembrolizumab) or Opdivo (nivolumab) therapy was not predicted by RNA expression levels of CD274 (PD-L1) in glioblastoma patients (PMID: 30742119). 30742119
CD274 positive renal cell carcinoma predicted - sensitive Avelumab + Axitinib Phase III Actionable In a Phase III trial (JAVELIN Renal 101), Inlyta (axitinib) plus Bavencio (avelumab) treatment resulted in a median progression-free survival of 13.8 mo. vs. 7.2 mo. with Sutent (sunitinib), and an objective response rate of 55.2% vs. 25.5% with Sutent (sunitinib) in patients with PD-L1-positive renal cell carcinoma, and at median follow-up 13.7% (37) of patients treated with Inlyta (axitinib) plus Bavencio (avelumab) had died vs. 15.2% (44) with Sutent (sunitinib) (PMID: 30779531; NCT02684006). 30779531
CD274 positive salivary gland carcinoma predicted - sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 12% (3/26) and a stable disease rate of 46% (12/26) in heavily pretreated patients with salivary gland carcinoma that had CD274 (PD-L1) expression in 1% or more of tumor or stroma cells by IHC, with a median duration of response of 4 months (PMID: 29462123; NCT02054806). detail... 29462123
CD274 positive malignant pleural mesothelioma predicted - sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in an objective response rate of 20% (5/25) and a stable disease rate of 52% (13/25) in previously treated patients with malignant pleural mesothelioma that had CD274 (PD-L1) expression in 1% or more of tumor cells by IHC, with a median duration of response of 12 months (PMID: 28291584; NCT02054806). 28291584
CD274 positive neuroendocrine tumor predicted - sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in objective response in 12% (3/25) of heavily pretreated patients with carcinoid tumors (lung, n=9; gut, n=7; other, n=9) and in 6% (1/16) of patients with pancreatic neuroendocrine tumors that had CD274 (PD-L1) expression in 1% or more of tumor cells by IHC, with stable disease in 60% (15/25) and 88% (14/16) of the patients respectively (Ann Oncol, 28(Suppl_5); NCT02054806). detail...
CD274 positive anal canal squamous cell carcinoma predicted - sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 17% (4/24) and stable disease in 42% (10/24) of patients with CD274 (PD-L1)-positive (1% or more) squamous cell carcinoma of the anal canal (PMID: 28453692; NCT02054806). 28453692
CD274 positive endometrial cancer predicted - sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 13% (3/24) and stable disease in 13% (3/24) of patients with heavily pretreated CD274 (PD-L1)-positive endometrial cancer (PMID: 28489510; NCT02054806). 28489510
CD274 positive nasopharynx carcinoma sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 25.9% (7/27) and stable disease in 51.9% (14/27) of patients with nasopharynx carcinoma that had CD274 (PD-L1) expression in 1% or more of tumor cells or tumor-infiltrating lymphocytes (PMID: 28837405; NCT02054806). 28837405
CD274 positive colorectal carcinoma predicted - sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 4% (1/24) and stable disease in 17% (4/24) of pretreated patients with CD274 (PD-L1)-positive colorectal carcinoma (PMID: 29284010; NCT02054806). 29284010
CD274 positive prostate adenocarcinoma predicted - sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 17.4% (4/23) and stable disease in 34.8% (8/23) of patients with CD274 (PD-L1)-positive (expression in 1% or more of tumor or stromal cells) advanced prostate adenocarcinoma (PMID: 29992241; NCT02054806). 29992241
CD274 positive Her2-receptor negative breast cancer predicted - sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 12% (3/25) and stable disease in 16% (4/25) of patients with CD274 (PD-L1)-positive (combined positive score >=1) advanced ER-positive, ERBB2 (HER2)-negative breast cancer, with a median duration of response of 12.0 months (PMID: 29559561; NCT02054806). 29559561
CD274 positive thyroid gland carcinoma predicted - sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in partial response in 9% (2/22) of patients with CD274 (PD-L1)-positive (1% or more) papillary (n=15) or follicular (n=7) thyroid carcinoma, with a median progression-free survival of 7 months (PMID: 30832606; NCT02054806). 30832606
CD274 positive lung small cell carcinoma sensitive Pembrolizumab Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in superior objective response rate (35.7%, 15/24 vs 6.0%, 3/50), median progression-free survival (2.1 vs 1.9 months), and median overall survival (14.6 vs 7.7 months) in patients with CD274 (PD-L1)-positive (combined positive score>=1) advanced small cell lung cancer compared to patients with CD274 (PD-L1)-negative tumors (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 8506-8506; NCT02628067). detail...
CD274 positive triple-receptor negative breast cancer sensitive Atezolizumab + Nab-paclitaxel Phase III Actionable In a Phase III trial (IMpassion130), Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) resulted in improved progression-free survival (7.5 vs 5.0 months, HR=0.62, p<0.001) and overall survival (25.0 vs 15.5 months, HR=0.62) compared to placebo in patients with CD274 (PD-L1)-positive (>1%), advanced triple-receptor negative breast cancer (PMID: 30345906; NCT02425891). detail... 30345906 detail...
CD274 positive lung non-squamous non-small cell carcinoma sensitive Nivolumab Phase III Actionable In a Phase III trial (CheckMate 057), Opdivo (nivolumab) treatment demonstrated greater overall survival, progression-free survival, and objective response rate at all CD274 (PD-L1) expression levels analyzed (1% or more, 5% or more, 10% and more) in nonsquamous non-small cell lung carcinoma patients (PMID: 26412456; NCT01673867). 26412456
CD274 positive esophageal carcinoma predicted - sensitive Pembrolizumab Pembrolizumab Phase I Actionable In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 30% (7/23, all partial responses), a median progression-free survival of 1.8 months, and a median overall survival of 7.0 months in patients with heavily pretreated, CD274 (PD-L1)-positive (1% or more) advanced esophageal carcinoma (PMID: 29116900; NCT02054806). 29116900
CD274 positive lung squamous cell carcinoma sensitive Carboplatin + Paclitaxel + Pembrolizumab Guideline Actionable Combination Paraplatin (carboplatin), Taxol (paclitaxel), and Keytruda (pembrolizumab) is in guidelines as preffered first-line therapy for patients with advanced or metastatic lung squamous cell carcinoma with CD274 (PD-L1) expression of greater than or equal to 1% and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung squamous cell carcinoma sensitive Carboplatin + Nab-paclitaxel + Pembrolizumab Guideline Actionable Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), and Keytruda (pembrolizumab) is in guidelines as preffered first-line therapy for patients with advanced or metastatic lung squamous cell carcinoma with CD274 (PD-L1) expression of greater than or equal to 1% and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive pancreatic cancer predicted - sensitive CBP501 + Cisplatin + Nivolumab Case Reports/Case Series Actionable In a Phase Ib trial, CBP501, Platinol (cisplatin), and Opdivo (nivolumab) triple combination therapy resulted in partial response in a patient with CD274 (PD-L1)-positive (70% tumor cells) pancreatic cancer (AACR Annual Meeting 2019, Abstract CT228; NCT03113188). detail...
CD274 positive head and neck squamous cell carcinoma sensitive Pembrolizumab Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase III trial (KEYNOTE-048) that supported FDA approval, Keytruda (pembrolizumab) monotherapy significantly improved overall survival compared to Erbitux (cetuximab) plus chemotherapy (12.3 vs 10.3 months, HR=0.78, p=0.0086) in patients with CD274 (PD-L1)-positive (CPS >=1) metastatic or unresectable recurrent head and neck squamous cell carcinoma (PMID: 31679945; NCT02358031). detail... 31679945 detail...
CD274 positive Advanced Solid Tumor predicted - sensitive CDX-527 Preclinical - Cell culture Actionable In a preclinical study, CDX-527 inhibited PD-1 signaling, and stimulated T cell response in culture (AACR Annual Meeting 2019, Abstract 2392). detail...
CD274 positive melanoma predicted - sensitive Pembrolizumab Pembrolizumab Clinical Study - Cohort Actionable In a clinical study, PD-L1 (CD274) expression in primary melanomas, but not the PD-L1 status of advancing edges or metastases, was associated with higher 6-month objective response rate (35.7% in PD-L1 positive vs. 5% in PD-L1 negative; p=0.02) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma (PMID: 29973670). 29973670
CD274 positive melanoma predicted - sensitive Nivolumab Clinical Study - Cohort Actionable In a clinical study, PD-L1 (CD274) expression in primary melanomas, but not the PD-L1 status of advancing edges or metastases, was associated with higher 6-month objective response rate (35.7% in PD-L1 positive vs. 5% in PD-L1 negative; p=0.02) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma (PMID: 29973670). 29973670
CD274 positive bladder urothelial carcinoma sensitive Atezolizumab Atezolizumab Phase II Actionable In a Phase II trial (IMvigor210), treatment with Tecentriq (atezolizumab) resulted in an objective response rate (ORR) of 23% (27/119) in cisplatin-ineligible patients with previously untreated, locally advanced or metastatic urothelial cancer, and ORR was 28% (9/32, 4 complete responses, 5 partial responses) in patients with immune cell CD274 (PD-L1) expression greater than or equal to 5% (PMID: 27939400; NCT02108652). 27939400
CD274 positive bladder urothelial carcinoma sensitive Pembrolizumab Pembrolizumab Phase II Actionable In a Phase II (KEYNOTE-052) trial, Keytruda (pembrolizumab) treatment resulted in objective response in 24% (89/370) of cisplatin-ineligible patients with urothelial cancer, patients with an expression of CD274 (PD-L1) over 10% demonstrated improved response, with an objective response rate of 38% (42/110) (PMID: 28967485; NCT02335424). 28967485
CD274 positive cervical cancer sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as second-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). detail...
CD274 positive esophagus squamous cell carcinoma sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a preferred second-line therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma with CD274 (PD-L1) expression (CPS >/=10) (NCCN.org). detail...
CD274 positive stomach cancer no benefit Toripalimab-tpzi Phase Ib/II Actionable In a Phase I/II trial, Loqtorz (toripalimab-tpzi) treatment resulted in an objective response rate (ORR) of 12.1% (7/58, 7 partial responses) and a disease control rate of 39.7% (23/58) in patients with advanced gastric cancer, the CD274 (PD-L1)-positive group demonstrated improved ORR (3/8, 37.5% vs 4/47, 8.5%, p=0.023) but not overall survival (12.1 vs 5.3 months, p=0.45) compared to the CD274 (PD-L1)-negative group (PMID: 31236579; NCT02915432). 31236579
CD274 positive Advanced Solid Tumor predicted - sensitive Toripalimab-tpzi Phase I Actionable In a Phase I trial, patients with CD274 (PD-L1)-positive (membrane staining in 1% or more of tumor cells, n=16) advanced solid tumors demonstrated improved objective response rate (ORR) (43.8% vs 0%, p=0.0081) and progression-free survival (HR=0.36, p=0.034) compared to CD274 (PD-L1)-negative (n=12) patients in response to Loqtorz (toripalimab-tpzi) treatment, with an ORR of 57.1% in CD274 (PD-L1)-high (membrane staining in >50% of tumor cells, n=7) patients (PMID: 30642373; NCT02836795). 30642373
CD274 positive gastric adenocarcinoma sensitive Pembrolizumab Pembrolizumab Phase II Actionable In a Phase II trial (KEYNOTE-059) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 15.5% (23/148, complete response 3, partial response 20) with a median response duration of 16.3 months in patients with CD274 (PD-L1)-positive (CPS >1) gastric cancer or gastroesophageal junction adenocarcinoma (PMID: 29543932; NCT02335411). 29543932
CD274 positive esophagus squamous cell carcinoma sensitive Pembrolizumab Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase III trial (KEYNOTE-181) that supported FDA approval, Keytruda (pembrolizumab) treatment as second-line therapy improved overall survival (OS) (9.3 vs 6.7 months, HR=0.69, p=0.0074) and 12-month OS rate (43% vs 20%) compared to chemotherapy in patients with esophagus squamous cell carcinoma with a CPS of 10 or higher (PMID: 33026938; NCT02564263). detail... detail... 33026938
CD274 positive lung non-small cell carcinoma sensitive SL-279252 Preclinical - Cell culture Actionable In a preclinical study, SL-279252 treatment coupled the activation of T-lymphocytes with induction of tumor cell apoptosis in a coculture of CD274-positive non-small cell lung cancer cells and CD3-positive T-lymphocytes (PMID: 30563566). 30563566
CD274 positive malignant peripheral nerve sheath tumor predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a clinical case study, Keytruda (pembrolizumab) treatment resulted in complete metabolic response after 4 cycles of treatment in a patient with CD274 (PD-L1)-positive malignant peripheral nerve sheath tumor, and the patient stayed on treatment for 21 cycles (PMID: 31383651). 31383651
CD274 positive lung large cell carcinoma sensitive Cisplatin + Pembrolizumab + Pemetrexed Disodium Guideline Actionable Combination Platinol (cisplatin), Alimta (pemetrexed disodium), and Keytruda (pembrolizumab) is in guidelines as preferred first-line therapy for patients with advanced or metastatic large cell lung cancer with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Carboplatin + Pembrolizumab + Pemetrexed Disodium Guideline Actionable Combination Paraplatin (carboplatin), Alimta (pemetrexed), and Keytruda (pembrolizumab) is in guidelines as preferred first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Guideline Actionable Combination Paraplatin (carboplatin), Taxol (paclitaxel), Avastin (bevacizumab), and Tecentriq (atezolizumab) is in guidelines as first-line therapy for patients with advanced or metastatic large cell lung cancer with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Guideline Actionable Combination Paraplatin (carboplatin), Taxol (paclitaxel), Avastin (bevacizumab), and Tecentriq (atezolizumab) is in guidelines as first-line therapy for patients with advanced or metastatic lung adenocarcinoma with CD274 (PD-L1) expression of greater than or equal to 1% and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Carboplatin + Pembrolizumab + Pemetrexed Disodium Guideline Actionable Combination Paraplatin (carboplatin), Alimta (pemetrexed), and Keytruda (pembrolizumab) is in guidelines as preferred first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Cisplatin + Pembrolizumab + Pemetrexed Disodium Guideline Actionable Combination Platinol (cisplatin), Alimta (pemetrexed disodium), and Keytruda (pembrolizumab) is in guidelines as preferred first-line therapy for patients with advanced or metastatic lung adenocarcinoma with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive head and neck squamous cell carcinoma sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive recurrent, unresectable, or metastatic non-nasopharyngeal head and neck squamous cell carcinoma (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma no benefit Nivolumab Phase III Actionable In a Phase III trial, treatment with Opdivo (nivolumab) did not result in longer median progression-free survival (PFS) or overall survival (OS) than chemotherapy treatment in patients with stage IV or recurrent non-small cell lung cancer with PD-L1 (CD274) expression of greater than 5%, resulting in a median PFS of 4.2 mo vs. 5.9 mo with chemotherapy (HR=1.15; 95% CI 0.91-1.45; p=0.25) and a median OS of 14.4 mo vs. 13.2 mo with chemotherapy (HR=1.15; 95% CI 0.80-1.30) (PMID: 28636851; NCT02041533). 28636851
CD274 positive lung non-small cell carcinoma sensitive Atezolizumab + Carboplatin + Nab-paclitaxel Guideline Actionable Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), and Tecetriq (atezolizumab) is in guidelines as first-line therapy for non-small cell lung cancer patients with CD274 (PD-L1) expression of greater than or equal to 1% (NCCN.org) detail...
CD274 positive bladder urothelial carcinoma sensitive Atezolizumab Atezolizumab Guideline Actionable Tecentriq (atezolizumab) is included in guidelines as a first-line therapy (category 2B) for cisplatin-ineligible bladder urothelial carcinoma patients with immune cell CD274 (PD-L1) expression greater than or equal to 5% (NCCN.org). detail...
CD274 positive vulva cancer sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a second-line therapy for patients with CD274 (PD-L1)-positive (CPS >= 1) vulva cancer (NCCN.org). detail...
CD274 positive lung adenocarcinoma predicted - sensitive Nab-paclitaxel + Pembrolizumab Case Reports/Case Series Actionable In a clinical case study, a lung adenocarcinoma patient with CD274 (PD-L1) expression of 30% and harboring CD74-ROS1 and ROS1 G2032K demonstrated a partial response after being treated with the combination therapy of Keytruda (pembrolizumab) and Abraxane (nab-paclitaxel) for two cycles (PMID: 32208297). 32208297
CD274 positive Hodgkin's lymphoma predicted - sensitive Pembrolizumab Pembrolizumab Phase Ib/II Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 60.0% (9/15, 2 complete response, 7 partial response) and a disease control rate of 80.0% in pediatric patients with CD274 (PD-L1)-positive Hodgkin's lymphoma, with a median progression-free survival of 12.2 months (PMID: 31812554; NCT02332668). 31812554
CD274 positive Advanced Solid Tumor predicted - sensitive Pembrolizumab Pembrolizumab Phase Ib/II Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 5.9% (8/136, 8 partial response) and a disease control rate of 26.5% in pediatric patients with CD274 (PD-L1)-positive advanced solid tumors, with a median progression-free survival of 1.9 months and a median overall survival of 9.0 months (PMID: 31812554; NCT02332668). 31812554
CD274 positive adrenocortical carcinoma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in 2 pediatric patients with CD274 (PD-L1)-positive adrenocortical carcinoma (PMID: 31812554; NCT02332668). 31812554
CD274 positive malignant mesothelioma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in 2 pediatric patients with CD274 (PD-L1)-positive mesothelioma (PMID: 31812554; NCT02332668). 31812554
CD274 positive ganglioglioma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in a pediatric patient with CD274 (PD-L1)-positive ganglioglioma (PMID: 31812554; NCT02332668). 31812554
CD274 positive epithelioid sarcoma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in a pediatric patient with CD274 (PD-L1)-positive epithelioid sarcoma (PMID: 31812554; NCT02332668). 31812554
CD274 positive lymphoepithelioma-like carcinoma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in a pediatric patient with CD274 (PD-L1)-positive lymphoepithelial carcinoma (PMID: 31812554; NCT02332668). 31812554
CD274 positive rhabdoid cancer predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in a partial response in a pediatric patient with CD274 (PD-L1)-positive rhabdoid cancer (PMID: 31812554; NCT02332668). 31812554
CD274 positive high grade glioma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in 2 pediatric patients with CD274 (PD-L1)-positive high-grade glioma (PMID: 31812554; NCT02332668). 31812554
CD274 positive embryonal rhabdomyosarcoma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in 2 pediatric patients with CD274 (PD-L1)-positive embryonal rhabdomyosarcoma (PMID: 31812554; NCT02332668). 31812554
CD274 positive sarcoma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in 2 pediatric patients with CD274 (PD-L1)-positive soft tissue sarcoma (PMID: 31812554; NCT02332668). 31812554
CD274 positive glioblastoma conflicting Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive glioblastoma (PMID: 31812554; NCT02332668). 31812554
CD274 positive chordoma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive chordoma (PMID: 31812554; NCT02332668). 31812554
CD274 positive high grade ependymoma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive ependymoma (PMID: 31812554; NCT02332668). 31812554
CD274 positive hepatoblastoma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive hepatoblastoma (PMID: 31812554; NCT02332668). 31812554
CD274 positive neuroblastoma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive neuroblastoma (PMID: 31812554; NCT02332668). 31812554
CD274 positive ganglioneuroblastoma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive ganglioneuroblastoma (PMID: 31812554; NCT02332668). 31812554
CD274 positive congenital mesoblastic nephroma predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive mesoblastic nephroma (PMID: 31812554; NCT02332668). 31812554
CD274 positive fibrosarcoma of bone predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive malignant histiocytosis (PMID: 31812554; NCT02332668). 31812554
CD274 positive inflammatory myofibroblastic tumor predicted - sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a Phase I/II trial (KEYNOTE-051), Keytruda (pembrolizumab) treatment resulted in size reduction of target lesion in a pediatric patient with CD274 (PD-L1)-positive inflammatory myofibroblastic tumor (PMID: 31812554; NCT02332668). 31812554
CD274 positive lung cancer predicted - sensitive MCLA-145 Preclinical - Cell line xenograft Actionable In a preclinical study, MCLA-145 treatment inhibited tumor growth in a cell line xenograft model of CD274 (PD-L1) and NY-ESO-positive lung cancer that had adoptive transfer of human T-cells expressing NY-ESO specific T-cell receptors (Cancer Res 2019;79(13 Suppl):Abstract nr 539). detail...
CD274 positive ovarian cancer predicted - sensitive Atezolizumab + Hu5F9-G4 Case Reports/Case Series Actionable In a Phase Ib trial, Tecentriq (atezolizumab) and Magrolimab (Hu5F9-G4) combination therapy resulted in tumor shrinkage in a patient with platinum-resistant ovarian cancer with tumor CD274 (PD-L1) expression (J Clin Oncol 38, 2020 (suppl 5; abstr 18); NCT03558139). detail...
CD274 positive lung non-small cell carcinoma predicted - sensitive Atezolizumab + Tiragolumab Phase II Actionable In a Phase II trial (CITYSCAPE), Tiragolumab (MTIG7192A) and Tecentriq (atezolizumab) combination therapy as first-line treatment improved objective response rate (37.3%, 25/67 vs 20.6%, 14/68) and median progression-free survival (5.6 vs 3.9 mo) compared to Tecentriq (atezolizumab) plus placebo in patients with CD274 (PD-L1)-positive (TPS>=1%) advanced or metastatic non-small cell lung cancer (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 9503-9503; NCT03563716). detail...
CD274 positive transitional cell carcinoma sensitive Avelumab Phase III Actionable In a Phase III trial (JAVELIN Bladder 100), addition of maintenance Bavencio (avelumab) to best supportive care (BSC) significantly improved overall survival compared to BSC alone (not reached vs 17.1 mo, HR=0.56, p=0.0003) in patients with CD274 (PD-L1)-positive advanced urothelial carcinoma (J Clin Oncol 38, (Jun 2020) no. 18_suppl; NCT02603432). detail...
CD274 positive Her2-receptor positive breast cancer not predictive Ado-trastuzumab emtansine Phase III Actionable In a retrospective analysis of a Phase III trial (KATHERINE), CD274 (PD-L1) expression was not associated with invasive disease-free survival (HR=1.05) in patients with Erbb2 (Her2)-positive breast cancer treated with adjuvant Kadcyla (ado-trastuzumab emtansine), who had residual invasive disease after neoadjuvant therapy (PMID: 36730339; NCT01772472). 36730339
CD274 positive Her2-receptor positive breast cancer predicted - sensitive Trastuzumab Phase III Actionable In a retrospective analysis of a Phase III trial (KATHERINE), CD274 (PD-L1) expression was associated with invasive disease-free survival (HR=0.66) in patients with Erbb2 (Her2)-positive breast cancer treated with adjuvant Herceptin (trastuzumab), who had residual invasive disease after neoadjuvant therapy (PMID: 36730339; NCT01772472). 36730339
CD274 positive lung adenocarcinoma sensitive Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Guideline Actionable Combination Paraplatin (carboplatin), Alimta (pemetrexed), Opdivo (nivolumab), and Yervoy (ipilimumab) is in guidelines as first-line therapy for patients with advanced or metastatic lung adenocarcinoma with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Guideline Actionable Combination Paraplatin (carboplatin), Alimta (pemetrexed), Opdivo (nivolumab), and Yervoy (ipilimumab) is in guidelines as first-line therapy for patients with advanced or metastatic large cell lung cancer with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Guideline Actionable Combination Paraplatin (carboplatin), Alimta (pemetrexed), Opdivo (nivolumab), and Yervoy (ipilimumab) is in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Guideline Actionable Combination Platinol (cisplatin), Alimta (pemetrexed), Opdivo (nivolumab), and Yervoy (ipilimumab) is in guidelines as first-line therapy for patients with advanced or metastatic lung adenocarcinoma with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Guideline Actionable Combination Platinol (cisplatin), Alimta (pemetrexed), Opdivo (nivolumab), and Yervoy (ipilimumab) is in guidelines as first-line therapy for patients with advanced or metastatic large cell lung cancer with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Guideline Actionable Combination Platinol (cisplatin), Alimta (pemetrexed), Opdivo (nivolumab), and Yervoy (ipilimumab) is in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung squamous cell carcinoma sensitive Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Guideline Actionable Combination Paraplatin (carboplatin), Taxol (paclitaxel), Opdivo (nivolumab), and Yervoy (ipilimumab) is in guidelines as first-line therapy for patients with advanced or metastatic lung squamous cell carcinoma, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is in guidelines as first-line therapy for patients with advanced or metastatic lung adenocarcinoma with CD274 (PD-L1) expression of 1% to 49% and as preferred first-line therapy with CD274 (PD-L1) expression of 50% or more, and negative for actionable molecular biomarkers; and as continued maintenance and subsequent therapy for patients with CD274 (PD-L1) expression of 1% or more (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is in guidelines as first-line therapy for patients with advanced or metastatic large cell lung cancer with CD274 (PD-L1) expression of 1% to 49% and as preferred first-line therapy with CD274 (PD-L1) expression of 50% or more, and negative for actionable molecular biomarkers; and as continued maintenance and subsequent therapy for patients with CD274 (PD-L1) expression of 1% or more (NCCN.org). detail...
CD274 positive lung squamous cell carcinoma sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is in guidelines as first-line therapy for patients with advanced or metastatic lung squamous cell carcinoma with CD274 (PD-L1) expression of 1% to 49% and as preferred first-line therapy with CD274 (PD-L1) expression of 50% or more, and negative for actionable molecular biomarkers; and as continued maintenance and subsequent therapy for patients with CD274 (PD-L1) expression of 1% or more (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Cisplatin + Pembrolizumab + Pemetrexed Disodium Guideline Actionable Combination Platinol (cisplatin), Alimta (pemetrexed disodium), and Keytruda (pembrolizumab) is in guidelines as preferred first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Carboplatin + Pembrolizumab + Pemetrexed Disodium Guideline Actionable Combination Paraplatin (carboplatin), Alimta (pemetrexed), and Keytruda (pembrolizumab) is in guidelines as preferred first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Guideline Actionable Combination Paraplatin (carboplatin), Taxol (paclitaxel), Avastin (bevacizumab), and Tecentriq (atezolizumab) is in guidelines as first-line therapy for patients with advanced or metastartic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Atezolizumab + Carboplatin + Nab-paclitaxel Guideline Actionable Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), and Tecetriq (atezolizumab) is in guidelines as first-line therapy for patients with large cell lung cancer with CD274 (PD-L1) expression of greater than or equal to 1%, and negative status for EGFR, ALK, ROS1, BRAF, RET, and MET exon 14 skipping mutations (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Atezolizumab + Carboplatin + Nab-paclitaxel Guideline Actionable Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), and Tecetriq (atezolizumab) is in guidelines as first-line therapy for patients with lung adenocarcinoma with CD274 (PD-L1) expression of greater than or equal to 1%, and negative status for EGFR, ALK, ROS1, BRAF, RET, and MET exon 14 skipping mutations (NCCN.org). detail...
CD274 positive melanoma predicted - sensitive Toripalimab-tpzi Phase II Actionable In a Phase II trial (POLARIS-01), Loqtorz (toripalimab-tpzi) resulted in a more favorable objective response rate (38.5% vs 11.9%, p=0.0065), disease control rate (80.8% vs 48.8%, p=0.006), progression-free survival (7.7 vs 2.7 mo, HR=0.53, p=0.013), and overall survival (not reached vs 14.4 mo, HR=0.35, p=0.0005) in patients with CD274 (PD-L1)-positive advanced melanoma (n=26) compared to patients with CD274 (PD-L1)-negative (n=84) tumors (PMID: 32321714; NCT03013101). 32321714
CD274 positive anal canal cancer predicted - sensitive Spartalizumab Case Reports/Case Series Actionable In a Phase I trial, Spartalizumab (PDR001) treatment in a patient with CD274 (PD-L1)-positive anal cancer resulted in a partial response lasting 1.8 months, with a combined 31% reduction of target lesion size (PMID: 32179633; NCT02404441). 32179633
CD274 positive anaplastic thyroid carcinoma predicted - sensitive Spartalizumab Phase II Actionable In a Phase II trial, Spartalizumab (PDR001) was tolerated in patients with anaplastic thyroid carcinoma, and resulted in an overall response rate (ORR) of 19% (8/42, 3 complete responses, 5 partial responses), median progression-free survival of 1.7 mo, and median overall survival of 5.9 mo; ORR was higher in patients with tumor PD-L1 >=1% compared to PD-L1<1% (29%, 8/28 vs 0%, 0/12, p=0.079), and highest ORR (35%) was observed in patients with PD-L1 >= 50% (PMID: 32364844; NCT02404441). 32364844
CD274 positive lung non-small cell carcinoma predicted - sensitive Nivolumab + Pegilodecakin Phase I Actionable In a Phase Ib trial (IVY), Pegilodecakin (AM0010) and Keytruda (pembrolizumab) (n=5) or Opdivo (nivolumab) (n=29) combination therapy demonstrated safety and preliminary efficacy in patients with non-small cell lung carcinoma, objective response was observed in 83% (5/6) of patients with CD274 (PD-L1) expression of 50% or higher, and in 67% (2/3) of patients with CD274 (PD-L1) expression less than 50% (PMID: 31563517; NCT02009449). 31563517
CD274 positive transitional cell carcinoma predicted - sensitive Nivolumab Phase II Actionable In a Phase II trial (CheckMate 275), Opdivo (nivolumab) treatment in platinum-resistant urothelial carcinoma patients resulted in an objective response rate (ORR) of 20.7% (56/270), a median progression-free survival (mPFS) of 1.9 mo., and a median overall survival (mOS) of 8.6 mo., and patients with CD274 (PD-L1)-positive tumors (IHC>=1% compared to <1%) had improved ORR (25.8%, 32/124 v 16.4%, 24/146), mPFS (3.5 v 1.9 mo), and mOS (11.9 v 6.0 mo) (PMID: 32532789; NCT02387996). 32532789
CD274 positive triple-receptor negative breast cancer sensitive Pembrolizumab Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase III trial (KEYNOTE-355) that supported FDA approval, addition of Keytruda (pembrolizumab) to chemotherapy significantly improved progression-free survival compared to chemotherapy alone (9.7 vs 5.6, HR=0.65, p=0.0012) in patients with locally recurrent or metastatic triple-receptor negative breast cancer expressing CD274 (PD-L1, CPS>=10), as determined by an FDA-approved test (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 1000-1000; NCT02819518). detail... detail... detail...
CD274 positive alveolar soft part sarcoma not predictive GB226 Phase II Actionable In a Phase II trial (Gxplore-005), patients with CD274 (PD-L1)-positive (CPS >=1%) alveolar soft part sarcoma achieved an objective response rate (ORR) of 33.3% (4/12; 95% CI 9.9-65.1) and a disease control rate (DCR) of 83.3% (10/12; 95% CI 51.6-97.9) in response to Geptanolimab (GB226) treatment, which were not different from the 40.0% ORR (10/25; 95% CI 21.1-61.3) and 88.0% DCR (22/25; 95% CI 68.8-97.5) observed in CD274 (PD-L1)-negative (CPS <1%) patients (PMID: 33046518; NCT03623581). 33046518
CD274 positive hepatocellular carcinoma not predictive Camrelizumab + Rivoceranib Clinical Study - Cohort Actionable In a Phase II trial (RESCUE), combined Camrelizumab (SHR-1210) and Rivoceranib (apatinib) treatment in patients with CD274 (PD-L1)-positive (TPS>=1%) advanced hepatocellular carcinoma demonstrated a similar objective response rate (31.8%, 7/22 vs. 18.8%, 6/32) and progression-free survival event rate (63.6%,14/22 vs. 75.0%, 24/32) compared to patients with CD274 (PD-L1)-negative (TPS<1%) tumors (PMID: 33087333; NCT03463876). 33087333
CD274 positive nasopharynx carcinoma sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a subsequent-line therapy for patients with CD274 (PD-L1)-positive, recurrent or metastatic nasopharynx cancer (NCCN.org). detail...
CD274 positive head and neck cancer sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first- and subsequent-line therapy for patients with CD274 (PD-L1)-positive (CPS >= 1) recurrent, unresectable, or metastatic non-nasopharyngeal head and neck cancer (NCCN.org). detail...
CD274 positive lung non-squamous non-small cell carcinoma not predictive Camrelizumab + Rivoceranib Phase Ib/II Actionable In a Phase Ib/II trial, combined Camrelizumab (SHR-1210) and Rivoceranib (apatinib) treatment in patients with CD274 (PD-L1)-positive (TPS>=1%; n=25) non-squamous non-small cell lung cancer resulted in a similar objective response rate (36.0%, 9/25 vs 22.7%, 15/66; p=0.20), disease control rate (72.0%,18/25 vs 71.2%, 47/66; p=0.94), and median progression-free survival (6.8 vs 5.1 months; p=0.29) to patients with CD274 (PD-L1)-negative (TPS<1%; n=66) tumors (PMID: 33323401; NCT03083041). 33323401
CD274 positive lung adenocarcinoma sensitive Pembrolizumab Pembrolizumab Case Reports/Case Series Actionable In a clinical case study, a patient with CD274 (PD-L1)-positive (70% tumor cells) metastatic lung adenocarcinoma treated with Keytruda (pembrolizumab) achieved a complete response in multiple brain metastases prior to disease progression in a primary lung lesion after 9 months of treatment, but was subsequently treated with Tepmetko (tepotinib) due to the presence of a MET exon 14 skipping mutation, which resulted in prolonged disease stabilization with no recurrence of brain lesions (PMID: 33335011). 33335011
CD274 positive diffuse large B-cell lymphoma predicted - sensitive CD19-PD-1/CD28-CAR T cells Case Reports/Case Series Actionable In a Phase Ib trial, CD19-PD-1/CD28-CAR T cell treatment in two patients with CD274 positive diffuse large B-cell lymphoma resulted in complete remission (CR) after 3 months, however, disease progression was observed in one patient after 2 months, while the other patient achieved persistent CR. (PMID: 33028589). 33028589
CD274 positive lung adenocarcinoma no benefit LMB-100 Preclinical - Cell culture Actionable In a preclinical study, a CD274 (PD-L1) positive mouse lung adenocarcinoma cell line was not sensitive to treatment with LMB-100 in culture (PMID: 32611684). 32611684
CD274 positive malignant mesothelioma predicted - sensitive Pembrolizumab Pembrolizumab Clinical Study Actionable In a clinical study, 80% (4/5) of MSLN positive mesothelioma patients with CD274 (PD-L1) expression who had progressed on LMB-100 demonstrated an objective response when treated with Keytruda (pembrolizumab), and compared to patients without CD274 expression (n=5), treatment significantly prolonged median progression-free survival (11.3 vs 2.1 mos, p<0.0018) but not overall survival (27.2 vs 6.8 mos, p=0.1) (PMID: 32611684). 32611684
CD274 positive triple-receptor negative breast cancer sensitive Nab-paclitaxel + Pembrolizumab Guideline Actionable Combination of Keytruda (pembrolizumab) and Abraxane (nab-paclitaxel) is included in guidelines for patients with recurrent or metastatic CD274 (PD-L1)-positive (CPS >or= 10) triple-receptor negative breast cancer (NCCN.org). detail...
CD274 positive triple-receptor negative breast cancer sensitive Paclitaxel + Pembrolizumab Guideline Actionable Combination of Keytruda (pembrolizumab) and Taxol (paclitaxel) is included in guidelines for patients with recurrent or metastatic CD274 (PD-L1)-positive (CPS >or= 10) triple-receptor negative breast cancer (NCCN.org). detail...
CD274 positive triple-receptor negative breast cancer sensitive Carboplatin + Gemcitabine + Pembrolizumab Guideline Actionable Combination of Keytruda (pembrolizumab), Paraplatin (carboplatin), and Gemzar (gemcitabine) is included in guidelines for patients with recurrent or metastatic CD274 (PD-L1)-positive (CPS >or= 10) triple-receptor negative breast cancer (NCCN.org). detail...
CD274 positive esophagus squamous cell carcinoma sensitive Cisplatin + Fluorouracil + Pembrolizumab Phase III Actionable In a Phase III trial (KEYNOTE-590), addition of Keytruda (pembrolizumab) to cisplatin and fluorouracil significantly improved overall survival (13.9 vs 8.8 mo, HR=0.57, p<0.0001) and progression-free survival (6.3 vs 5.8 mo, HR=0.65, p<0.0001) in patients with metastatic or locally advanced esophageal squamous cell carcinoma expressing PD-L1 (CPS>=10) (Ann Oncol. 31, no. 4_suppl (Sep 2020) S1192-S1193; NCT03189719). detail...
CD274 positive esophageal carcinoma sensitive Cisplatin + Fluorouracil + Pembrolizumab Phase III Actionable In a Phase III trial (KEYNOTE-590), addition of Keytruda (pembrolizumab) to cisplatin and fluorouracil significantly improved overall survival (13.5 vs 9.4 mo, HR=0.62, p<0.0001) and progression-free survival (7.5 vs 5.5 mo, HR=0.51, p<0.0001) in patients with metastatic or locally advanced esophageal or gastroesophageal junction carcinoma expressing PD-L1 (CPS>=10) (Ann Oncol. 31, no. 4_suppl (Sep 2020) S1192-S1193; NCT03189719). detail...
CD274 positive gastroesophageal junction adenocarcinoma sensitive Cisplatin + Fluorouracil + Pembrolizumab Phase III Actionable In a Phase III trial (KEYNOTE-590), addition of Keytruda (pembrolizumab) to cisplatin and fluorouracil significantly improved overall survival (13.5 vs 9.4 mo, HR=0.62, p<0.0001) and progression-free survival (7.5 vs 5.5 mo, HR=0.51, p<0.0001) in patients with metastatic or locally advanced esophageal or gastroesophageal junction carcinoma expressing PD-L1 (CPS>=10) (Ann Oncol. 31, no. 4_suppl (Sep 2020) S1192-S1193; NCT03189719). detail...
CD274 positive lung non-small cell carcinoma predicted - sensitive Durvalumab Phase II Actionable In a Phase II trial (ATLANTIC), Imfinzi (durvalumab) treatment resulted in superior objective response rate in non-small cell lung cancer patients with 25% or more tumor cells expressing CD274 (PD-L1) compared to patients with CD274 (PD-L1) expression in less than 25% of tumor cells, in both the cohort harboring EGFR and ALK mutations (12.2% vs 3.6%) and the EGFR and ALK wild-type cohort (16.4% vs 7.5%) (PMID: 29545095; NCT02087423). 29545095
CD274 positive esophagus squamous cell carcinoma predicted - sensitive Tislelizumab Clinical Study - Cohort Actionable In a Phase III trial (RATIONALE-302), second-line Tevimbra (tislelizumab) improved median overall survival (mOS) (8.6 vs 6.3 mo; HR 0.70, p=0.0001) and objective response rate (20.3% vs 9.8%) compared to chemotherapy in advanced esophageal squamous cell carcinoma patients, and CD274 (PD-L1)-positive (TAP>=10%) patients treated with Tevimbra (tislelizumab) (n=89) showed improved mOS (10.3 vs 6.8 mo; HR 0.54, p=0.0006) compared to those patients treated with chemotherapy (n=68) (PMID: 35442766; NCT03430843). 35442766
CD274 positive transitional cell carcinoma predicted - sensitive Retifanlimab Phase II Actionable In a Phase II trial (POD1UM-203), Zynyz (retifanlimab) treatment was well tolerated and demonstrated antitumor activity in patients with CD274 (PD-L1)-positive urothelial cancer, resulting in an objective response rate of 37.9% (11/29) and a disease control rate of 55.2% (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2571-2571; NCT03679767). detail...
CD274 positive gastroesophageal junction adenocarcinoma unknown HX008 + Irinotecan Phase II Actionable In a Phase II trial, CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients treated with HX008 and Camptosar (irinotecan) achieved an objective response rate (ORR) of 38.5% (5/13), disease control rate (DCR) of 84.6% (11/13), median progression-free survival (mPFS) of 4.3 mo, and median overall survival (mOS) was not reached, compared to CD274 (PD-L1) negative patients with an ORR of 37.5% (3/8), DCR of 75% (6/8), mPFS of 5.0 mo, and mOS of 8.7 mo (PMID: 33060149; NCT03704246). 33060149
CD274 positive stomach cancer unknown HX008 + Irinotecan Phase II Actionable In a Phase II trial, CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients treated with HX008 and Camptosar (irinotecan) achieved an objective response rate (ORR) of 38.5% (5/13), disease control rate (DCR) of 84.6% (11/13), median progression-free survival (mPFS) of 4.3 mo, and median overall survival (mOS) was not reached, compared to CD274 (PD-L1) negative patients with an ORR of 37.5% (3/8), DCR of 75% (6/8), mPFS of 5.0 mo, and mOS of 8.7 mo (PMID: 33060149; NCT03704246). 33060149
CD274 positive rectum cancer predicted - sensitive OH2 Case Reports/Case Series Actionable In a Phase I/II trial, a patient with CD274 (PD-L1)-positive (TPS=3) metastatic rectal cancer treated with OH2 in a liver metastasis achieved a partial response with reduced size of the injected and non-injected liver lesions 6.89 months after treatment initiation and discontinued treatment but maintained an ongoing response lasting over 11.25 months (PMID: 33837053). 33837053
CD274 positive esophageal cancer predicted - sensitive OH2 Case Reports/Case Series Actionable In a Phase I/II trial, OH2 treatment in a CD274 (PD-L1)-positive (TPS=3) metastatic esophageal cancer patient led to an immune partial response 5.44 months after treatment initiation, followed by discontinuation of treatment, and an ongoing response lasting over 14.03 months (PMID: 33837053). 33837053
CD274 positive stomach cancer not predictive Capecitabine + HX008 + Oxaliplatin Phase I Actionable In a Phase Ib trial, treatment with HX008, Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination therapy resulted in an objective response rate (ORR) of 75% (9/12) and disease control rate (DCR) of 83.3% (10/12) in CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients, compared to an ORR and DCR of 66.7% (6/9) and 100% (9/9) respectively in CD274 (PD-L1)-negative patients; however, no difference was observed in progression-free survival (p=0.19) (PMID: 33457083). 33457083
CD274 positive gastroesophageal junction adenocarcinoma not predictive Capecitabine + HX008 + Oxaliplatin Phase I Actionable In a Phase Ib trial, treatment with HX008, Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination therapy resulted in an objective response rate (ORR) of 75% (9/12) and disease control rate (DCR) of 83.3% (10/12) in CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients, compared to an ORR and DCR of 66.7% (6/9) and 100% (9/9) respectively in CD274 (PD-L1)-negative patients; however, no difference was observed in progression-free survival (p=0.19) (PMID: 33457083). 33457083
CD274 positive triple-receptor negative breast cancer predicted - sensitive Eribulin + Pembrolizumab Phase Ib/II Actionable In a Phase I/II trial, Keytruda (pembrolizumab) and Eribulin combination therapy demonstrated safety and clinical activity in patients with metastatic triple-negative breast cancer, patients with CD274 (PD-L1)-positive tumors achieved better objective response rate (28.4% vs 17.3%), median progression-free survival (4.2 vs 3.9 months), and overall survival (16.3 vs 15.2 months) compared to patients with CD274 (PD-L1)-negative tumors (PMID: 33727258; NCT02513472). 33727258
CD274 positive stomach cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab), in combination with first-line chemotherapy including fluoropyrimidine and oxaliplatin, is included in guidelines as preferred first-line therapy for patients with gastric cancer expressing PD-L1 (CD274, CPS>=5), and without ERBB2 (HER2) overexpression (category 1), and as first-line therapy for patients with PD-L1 expression (CD274, CPS <5) and without ERBB2 (HER2) overexpression (category 2B) (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Ipilimumab + Nivolumab Ipilimumab + Nivolumab Guideline Actionable Combination Opdivo (nivolumab) plus Yervoy (ipilimumab) is in guidelines as first-line or continuation maintenance therapy for advanced or metastatic non-small cell lung cancer patients with CD274 (PD-L1) expression >1% and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive transitional cell carcinoma predicted - sensitive Nivolumab Phase III Actionable In a Phase III trial (CheckMate-274), adjuvant Opdivo (nivolumab) treatment significantly improved the percentage of patients who were alive and disease-free at 6 months (74.5% vs 55.7%, HR 0.55, P<0.001) and median recurrence-free survival (22.9 vs 13.7 mo) compared to placebo in patients with high-risk urothelial carcinoma with a PD-L1 expression level of 1% or more (PMID: 34077643; NCT02632409). 34077643
CD274 positive esophageal cancer sensitive Capecitabine + Oxaliplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative esophageal adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS <10 (category 2B) (NCCN.org). detail...
CD274 positive gastroesophageal junction adenocarcinoma sensitive Capecitabine + Oxaliplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS >/=1 and <10 (category 2B) (NCCN.org). detail...
CD274 positive gastroesophageal junction adenocarcinoma sensitive Cisplatin + Fluorouracil + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS >/=1 and <10 (category 2B) (NCCN.org). detail...
CD274 positive gastroesophageal junction adenocarcinoma sensitive Capecitabine + Cisplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS >/=1 and <10 (category 2B) (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma predicted - sensitive Anlotinib + Cadonilimab Phase Ib/II Actionable In a Phase Ib/II trial, combination treatment with Cadonilimab and Anlotinib (AL-3818) demonstrated antitumor activity in patients with CD274 (PD-L1) positive (TPS >= 1%) non-small cell lung cancer, and led to an objective response rate of 62.5% (5/8) and a disease control rate of 100% (8/8). (Annals of Oncology 32 (2021): S1006; NCT04646330). detail...
CD274 positive cervical cancer sensitive Cisplatin + Paclitaxel + Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase III trial (KEYNOTE-826) that supported FDA approval, first-line Keytruda (pembrolizumab) in combination with platinum-based chemotherapy (Platinol (cisplatin) or Paraplatin (carboplatin) plus Taxol (paclitaxel)), with or without Avastin (bevacizumab), improved progression-free survival (10.4 vs 8.1 mo, HR 0.62, p<0.001) compared to placebo in patients with CD274 (PD-L1)-positive (CPS>=1), persistent, recurrent or metastatic cervical cancer (PMID: 34534429; NCT03635567). 34534429 detail... detail...
CD274 positive cervical cancer sensitive Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase III trial (KEYNOTE-826) that supported FDA approval, first-line Keytruda (pembrolizumab) in combination with platinum-based chemotherapy (Platinol (cisplatin) or Paraplatin (carboplatin) plus Taxol (paclitaxel)), with or without Avastin (bevacizumab), improved progression-free survival (10.4 vs 8.1 mo, HR 0.62, p<0.001) compared to placebo in patients with CD274 (PD-L1)-positive (CPS>=1), persistent, recurrent or metastatic cervical cancer (PMID: 34534429; NCT03635567). 34534429 detail... detail...
CD274 positive cervical cancer sensitive Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase III trial (KEYNOTE-826) that supported FDA approval, first-line Keytruda (pembrolizumab) in combination with platinum-based chemotherapy (Platinol (cisplatin) or Paraplatin (carboplatin) plus Taxol (paclitaxel)), with or without Avastin (bevacizumab), improved progression-free survival (10.4 vs 8.1 mo, HR 0.62, p<0.001) compared to placebo in patients with CD274 (PD-L1)-positive (CPS>=1), persistent, recurrent or metastatic cervical cancer (PMID: 34534429; NCT03635567). detail... detail... 34534429
CD274 positive cervical cancer sensitive Carboplatin + Paclitaxel + Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase III trial (KEYNOTE-826) that supported FDA approval, first-line Keytruda (pembrolizumab) in combination with platinum-based chemotherapy (Platinol (cisplatin) or Paraplatin (carboplatin) plus Taxol (paclitaxel)), with or without Avastin (bevacizumab), improved progression-free survival (10.4 vs 8.1 mo, HR 0.62, p<0.001) compared to placebo in patients with CD274 (PD-L1)-positive (CPS>=1), persistent, recurrent or metastatic cervical cancer (PMID: 34534429; NCT03635567). detail... 34534429 detail...
CD274 positive lung non-small cell carcinoma sensitive Atezolizumab Atezolizumab FDA approved - On Companion Diagnostic Actionable In a Phase III trial (IMpower010) that supported FDA approval, adjuvant Tecentriq (atezolizumab) treatment following resection and chemotherapy improved disease-free survival compared to best supportive care (HR 0·66, p=0·0039) in patients with stage II-IIIA non-small cell lung cancer whose tumors expressed CD274 (PD-L1) on 1% or more of tumor cells (PMID: 34555333; NCT02486718). detail... 34555333 detail...
CD274 positive lung non-small cell carcinoma predicted - sensitive Durvalumab + Vactosertib Phase Ib/II Actionable In a Phase Ia/II trial, combination treatment with Vactosertib (TEW 7197) and Imfinzi (durvalumab) demonstrated safety and antitumor activity in CD274 (PD-L1)-positive non-small cell lung cancer patients, and led to an objective response rate of 30.8% and 40.0% in patients with CD274 (PD-L1) expression >= 1% and >=25% respectively (Journal for ImmunoTherapy of Cancer 2020;8; NCT03732274). detail...
CD274 positive lung non-small cell carcinoma sensitive Atezolizumab Atezolizumab Guideline Actionable Tecentriq (atezolizumab) is included in guidelines as adjuvant therapy for non-small cell lung cancer patients with PD-L1 expression >/= 1% and negative for EGFR exon 19 deletion, L858R, or ALK rearrangements who have received prior adjuvant chemotherapy (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma predicted - sensitive Niraparib + Pembrolizumab Phase II Actionable In a Phase II trial, combination Zejula (niraparib) and Keytruda (pembrolizumab) resulted in an objective response rate (ORR) of 56.3% (9/16; 2 complete, 7 partial responses), 19.7-mo median duration of response (mDR), and 8.4-mo median progression-free survival (mPFS) in non-small cell lung cancer patients with a CD274 (PD-L1) TPS>=50%, and an ORR of 20% (4/20; 4 partial responses), 9.4-mo mDR, and 4.2-mo mPFS in patients with a CD274 (PD-L1) TPS=1-49% (PMID: 34478166; NCT03308942). 34478166
CD274 positive cervical cancer sensitive Bevacizumab + Cisplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) combined with Platinol (cisplatin) and Avastin (bevacizumab) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). detail...
CD274 positive cervical cancer sensitive Bevacizumab + Paclitaxel + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) combined with Taxol (paclitaxel) and Avastin (bevacizumab) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). detail...
CD274 positive cervical cancer sensitive Bevacizumab + Carboplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) combined with Paraplatin (carboplatin) and Avastin (bevacizumab) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). detail...
CD274 positive cervical cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as second-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). detail...
CD274 positive cervical cancer sensitive Cisplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) combined with Platinol (cisplatin) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). detail...
CD274 positive cervical cancer sensitive Paclitaxel + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) combined with Taxol (paclitaxel) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). detail...
CD274 positive cervical cancer sensitive Carboplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) combined with Paraplatin (carboplatin) is included in guidelines as first-line therapy for patients with CD274 (PD-L1)-positive cervical cancer (NCCN.org). detail...
CD274 positive sarcoma predicted - sensitive Doxorubicin + Pembrolizumab Phase II Actionable In a Phase II trial, Keytruda (pembrolizumab) and Adriamycin (doxorubicin) combination treatment resulted in a greater overall response rate (63.6% vs 22.2%, p=0.048) in patients with metastatic or unresectable anthracycline-naive soft-tissue sarcomas with a CD274 (PD-L1) H-score >=5% compared to those with a H-score less than 5% (PMID: 34475102; NCT03056001). 34475102
CD274 positive triple-receptor negative breast cancer sensitive Atezolizumab + Nab-paclitaxel Guideline Actionable The combination of Tecentriq (atezolizumab) and Abraxane (nab-paclitaxel) is included in guidelines as first line therapy for CD274 (PD-L1)-positive patients with triple-negative breast cancer (PMID: 34678411; ESMO.org). 34678411 detail...
CD274 positive triple-receptor negative breast cancer sensitive Pembrolizumab Pembrolizumab Guideline Actionable The combination of Keytruda (pembrolizumab) plus chemotherapy such as Taxol (paclitaxel), Abraxane (nab-paclitaxel), or Paraplatin (carboplatin) plus Gemzar (gemcitabine) is included in guidelines as first line therapy for CD274 (PD-L1)-positive patients with triple-negative breast cancer (PMID: 34678411; ESMO.org). detail... 34678411
CD274 positive colon cancer sensitive CS1003 Preclinical Actionable In a preclinical study, CS1003 inhibited tumor growth in a xenograft model of CD274 (PD-L1)-positive colon cancer (PMID: 32467569). 32467569
CD274 positive transitional cell carcinoma predicted - sensitive Toripalimab-tpzi Phase II Emerging In a Phase II trial (POLARIS-03), CD274 (PD-L1)-positive urothelial carcinoma patients (n=48) had an improved objective response rate (42% vs 17%, p=0.002) and median progression-free survival (3.7 months vs 1.8 months; p=0.001) compared to patients without CD274 (PD-L1) expression (n=96) following treatment with Loqtorz (toripalimab-tpzi) (PMID: 34740921; NCT03113266). 34740921
CD274 positive cervical squamous cell carcinoma predicted - sensitive Anlotinib + Sintilimab Phase II Actionable In a Phase II study, a combination of Anlotinib (AL-3818) and Sintilimab (IBI308) resulted in a significantly higher objective response rate in CD274 (PD-L1)-positive cervical squamous cell carcinoma patients compared to non-squamous cell cervical cancer patients, 69.7% (23/33) versus 0% (0/6), respectively (P=0.003), and longer median progression-free survival, 11.1 months vs 5.8 months, respectively (P=0.01) (PMID: 35192397). 35192397
CD274 positive cervical cancer predicted - sensitive Anlotinib + Sintilimab Phase II Actionable In a Phase II study, a combination of Anlotinib (AL-3818) and Sintilimab (IBI308) resulted in an objective response rate of 54.8% (23/42, 2 complete responses and 21 partial responses) in CD274 (PD-L1)-positive recurrent or metastatic cervical cancer patients, and led to a disease control rate of 88.1% (37/42, 14 with stable disease), a median progression-free survival (PFS) of 9.4 mos and a 6-mo PFS rate of 73.1%, a median overall survival (OS) not reached, and a 12-mo OS rate of 73.8% (PMID: 35192397). 35192397
CD274 positive cervical cancer predicted - sensitive Balstilimab + Zalifrelimab Phase II Actionable In a Phase II study, a combination of Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884) resulted in an objective response rate of 32.8% (22/67) in patients with recurrent and/or metastatic cervical cancer positive for CD274 (PD-L1) (PMID: 34932394; NCT03495882). 34932394
CD274 positive cervical adenocarcinoma predicted - sensitive Camrelizumab Case Reports/Case Series Actionable In a clinical case study, Camrelizumab (SHR-1210) treatment resulted in a partial response in the cervical tumor and a complete response in the pulmonary metastases in a patient with CD274 (PD-L1)-positive (IHC = 1%) cervical adenocarcinoma, who previously progressed on chemotherapy treatment (PMID: 35280424). 35280424
CD274 positive ovarian cancer predicted - sensitive Pimivalimab Case Reports/Case Series Actionable In a Phase I trial, Pimivalimab (JTX-4014) treatment led to a partial response lasting 232 days in a patient with CD274 (PD-L1)-positive (5% staining) ovarian cancer (PMID: 32989552; NCT03790488). 32989552
CD274 positive mucoepidermoid carcinoma predicted - sensitive Pimivalimab Case Reports/Case Series Actionable In a Phase I trial, Pimivalimab (JTX-4014) treatment led to a complete response that was ongoing for at least 338 days in a patient with CD274 (PD-L1)-positive (60% staining) mucoepidermoid carcinoma of the parotid (PMID: 32989552; NCT03790488). 32989552
CD274 positive head and neck squamous cell carcinoma sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with CD274 (PD-L1)-positive (CPS >/=1) recurrent or metastatic head and neck squamous cell carcinoma (PMID: 34844180; ESMO.org). detail... 34844180
CD274 positive head and neck squamous cell carcinoma sensitive Cisplatin + Fluorouracil + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with platinum and Adrucil (fluorouracil) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with CD274 (PD-L1)-positive (CPS >/=1) recurrent or metastatic head and neck squamous cell carcinoma (PMID: 34844180; ESMO.org). detail... 34844180
CD274 positive head and neck squamous cell carcinoma sensitive Carboplatin + Fluorouracil + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with platinum and Adrucil (fluorouracil) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with CD274 (PD-L1)-positive (CPS >/=1) recurrent or metastatic head and neck squamous cell carcinoma (PMID: 34844180; ESMO.org). 34844180 detail...
CD274 positive anal canal squamous cell carcinoma predicted - sensitive Retifanlimab Phase II Actionable In a Phase II trial (POD1UM-202), Zynyz (retifanlimab) treatment resulted in an objective response rate of 13.8% (13/94, 1 complete response, 12 partial responses), a disease control rate of 48.9%, and a median progression-free survival of 7.4 mo (patients with disease control) in patients with advanced or metastatic anal canal squamous carcinoma, with a significant correlation between tumor PD-L1 (CD274) expression and overall survival (p=0.0088) (PMID: 35816951; NCT03597295). 35816951
CD274 positive stomach cancer no benefit Nivolumab + Paclitaxel Phase II Actionable In a Phase II trial (K-Umbrella), Opdivo (nivolumab) and Taxol (paclitaxel) combination therapy improved median overall survival (10.7 vs 8.7 months, p=0.046) but not median progression-free survival (3.9 vs 4.0 months) in patients with advanced ERBB2 (HER2)-negative gastric cancer that was MSI high, mismatch repair deficient, or PD-L1 (CD274)-positive compared to standard of care in the control group (PMID: 37883723; NCT02951091). 37883723
CD274 positive ovarian carcinoma predicted - sensitive Durvalumab + Trabectedin Case Reports/Case Series Actionable In a Phase Ib trial (TRAMUNE), Yondelis (trabectedin) plus Imfinzi (durvalumab) demonstrated safety and resulted in an objective response rate of 21.4% (3/14, all partial responses), 3- and 6-month progression-free rates of 42.9% and 42.9%, a 1-year progression-free survival (PFS) rate of 7.1%, and a 1-year overall survival rate of 57.1% in patients with ovarian carcinoma, with an improved PFS for patients with CD274 (PD-L1) expression (6.8 mo vs 1.3 mo) (PMID: 34965951; NCT03085225). 34965951
CD274 positive lung non-small cell carcinoma predicted - sensitive MT-6402 Case Reports/Case Series Actionable In a Phase I trial, MT-6402 treatment led to an antitumor immune response and decreased metastatic bone lesions in a CD274 (PD-L1)-positive non-small cell lung cancer patient with osseous metastases (Cancer Res 2022;82(12_Suppl):Abstract nr CT152). detail...
CD274 positive Advanced Solid Tumor predicted - resistant MT-6402 Preclinical - Cell culture Actionable In a preclinical study, MT-6402 treatment demonstrated cytotoxicity in a panel of CD274 (PD-L1)-positive cancer cell lines in culture (Cancer Res 2022;82(12_Suppl):Abstract nr CT152). detail...
CD274 positive Advanced Solid Tumor sensitive GEN1046 Preclinical Actionable In a preclinical study, GEN1046 treatment resulted in T-cell activation and proliferation and induced T-cell-mediated cytotoxicity of CD274 (PD-L1)-positive tumor cells in culture, and induced tumor regression in a transgenic mouse model expressing human CD274 (PD-L1) (PMID: 35176764). 35176764
CD274 positive ovary epithelial cancer predicted - sensitive Atezolizumab Atezolizumab Case Reports/Case Series Actionable In a Phase I trial, Tecentriq (atezolizumab) treatment resulted in an objective response rate (ORR) of 22.2% (2/9, 1 complete response, 1 partial response) and a median progression-free survival of 2.9 months in patients with advanced or recurrent ovarian epithelial cancer, ORR was 25% (2/8) in patients with tumor CD274 (PD-L1) expression of 5% or higher and 0% (0/1) in patients with tumor CD274 (PD-L1) expression below 5% (PMID: 31204078; NCT01375842). 31204078
CD274 positive uterine cancer predicted - sensitive Atezolizumab Atezolizumab Case Reports/Case Series Actionable In a Phase I trial, Tecentriq (atezolizumab) treatment resulted in an objective response rate (ORR) of 13.3% (2/15, 2 partial responses) and a median progression-free survival of 1.4 months in patients with advanced or recurrent uterine cancer, ORR was 40% (2/5) in patients with tumor CD274 (PD-L1) expression of 5% or higher and 0% (0/10) in patients with tumor CD274 (PD-L1) expression below 5% (PMID: 31204078; NCT01375842). 31204078
CD274 positive stomach cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated gastric cancer expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org). detail... 35914639
CD274 positive gastroesophageal junction adenocarcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated gastroesophageal junction adenocacinoma expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org). detail... 35914639
CD274 positive esophageal cancer sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated esophageal cancer expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org). 35914639 detail...
CD274 positive gastroesophageal junction adenocarcinoma sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with advanced or metastatic gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274, CPS>=10) (PMID: 35914639; ESMO.org). 35914639 detail...
CD274 positive esophagus adenocarcinoma sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with advanced or metastatic esophageal adenocarcinoma expressing PD-L1 (CD274, CPS>=10) (PMID: 35914639; ESMO.org). 35914639 detail...
CD274 positive esophagus squamous cell carcinoma sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, CPS>=10), and as second or subsequent lines of treatment for previously treated patients who have not received immunotherapy and with CPS>=10 (PMID: 35914638; ESMO.org). detail... 35914638
CD274 positive esophagus squamous cell carcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, TPS>=1%) (PMID: 35914638; ESMO.org). detail... 35914638
CD274 positive esophagus squamous cell carcinoma sensitive Ipilimumab + Nivolumab Ipilimumab + Nivolumab Guideline Actionable Yervoy (ipilimumab) in combination with Opdivo (nivolumab) is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, TPS>=1%) (PMID: 35914638; ESMO.org). 35914638 detail...
CD274 positive melanoma predicted - sensitive Cetrelimab Phase Ib/II Actionable In a Phase I/II trial, Cetrelimab (JNJ-63723283) treatment demonstrated safety, and resulted in an overall response rate (ORR) of 18.6% (38/204), clinical benefit rate (CBR) of 31.3% (64/204), median progression-free survival (mPFS) of 2.8 mo, and median overall survival (mOS) of 17.8 mo in advanced solid tumor patients, with an ORR of 50% (4/8, 1 complete and 3 partial responses), and CBR of 75% (6/8) in CD274 (PD-L1)-positive melanoma patients (PMID: 35298698; NCT02908906). 35298698
CD274 positive lung adenocarcinoma sensitive Ipilimumab + Nivolumab Ipilimumab + Nivolumab Guideline Actionable Combination Opdivo (nivolumab) plus Yervoy (ipilimumab) is in guidelines as first-line or continuation maintenance therapy for advanced or metastatic lung adenocarcinoma patients with CD274 (PD-L1) expression >1% and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Ipilimumab + Nivolumab Ipilimumab + Nivolumab Guideline Actionable Combination Opdivo (nivolumab) plus Yervoy (ipilimumab) is in guidelines as first-line or continuation maintenance therapy for advanced or metastatic large cell lung cancer patients with CD274 (PD-L1) expression >1% and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung squamous cell carcinoma sensitive Ipilimumab + Nivolumab Ipilimumab + Nivolumab Guideline Actionable Combination Opdivo (nivolumab) plus Yervoy (ipilimumab) is in guidelines as first-line or continuation maintenance therapy for advanced or metastatic lung squamous cell carcinoma patients with CD274 (PD-L1) expression >1% and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung squamous cell carcinoma sensitive Carboplatin + Cemiplimab + Paclitaxel Guideline Actionable Combination Paraplatin (carboplatin), Taxol (paclitaxel), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic squamous cell lung cancer with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Carboplatin + Cemiplimab + Paclitaxel Guideline Actionable Combination Paraplatin (carboplatin), Taxol (paclitaxel), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Carboplatin + Cemiplimab + Paclitaxel Guideline Actionable Combination Paraplatin (carboplatin), Taxol (paclitaxel), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic large cell lung cancer with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Carboplatin + Cemiplimab + Paclitaxel Guideline Actionable Combination Paraplatin (carboplatin), Taxol (paclitaxel), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic lung adenocarcinoma with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Cemiplimab + Cisplatin + Paclitaxel Guideline Actionable Combination Platinol (cisplatin), Taxol (paclitaxel), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Cemiplimab + Cisplatin + Paclitaxel Guideline Actionable Combination Platinol (cisplatin), Taxol (paclitaxel), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic large cell lung cancer with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Cemiplimab + Cisplatin + Paclitaxel Guideline Actionable Combination Platinol (cisplatin), Taxol (paclitaxel), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic lung adenocarcinoma with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung squamous cell carcinoma sensitive Cemiplimab + Cisplatin + Paclitaxel Guideline Actionable Combination Platinol (cisplatin), Taxol (paclitaxel), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic squamous cell lung cancer with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Carboplatin + Cemiplimab + Pemetrexed Disodium Guideline Actionable Combination Paraplatin (carboplatin), Alimta (pemetrexed disodium), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Carboplatin + Cemiplimab + Pemetrexed Disodium Guideline Actionable Combination Paraplatin (carboplatin), Alimta (pemetrexed disodium), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic large cell lung cancer, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Carboplatin + Cemiplimab + Pemetrexed Disodium Guideline Actionable Combination Paraplatin (carboplatin), Alimta (pemetrexed disodium), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic lung adenocarcinoma, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Cemiplimab + Cisplatin + Pemetrexed Disodium Guideline Actionable Combination Platinol (cisplatin), Alimta (pemetrexed disodium), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic lung adenocarcinoma, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Cemiplimab + Cisplatin + Pemetrexed Disodium Guideline Actionable Combination Platinol (cisplatin), Alimta (pemetrexed disodium), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic large cell lung cancer, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Cemiplimab + Cisplatin + Pemetrexed Disodium Guideline Actionable Combination Platinol (cisplatin), Alimta (pemetrexed disodium), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Guideline Actionable Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression >/=1% - 49% (category 1) or >/= 50% (category 2B), and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Guideline Actionable Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic large cell lung cancer, with CD274 (PD-L1) expression >/=1% - 49% (category 1) or >/= 50% (category 2B), and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Guideline Actionable Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic lung adenocarcinoma, with CD274 (PD-L1) expression >/=1% - 49% (category 1) or >/= 50% (category 2B), and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Guideline Actionable Combination Paraplatin (carboplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression >/=1% - 49% (category 1) or >/= 50% (category 2B), and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Guideline Actionable Combination Paraplatin (carboplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic lung adenocarcinoma, with CD274 (PD-L1) expression >/=1% - 49% (category 1) or >/= 50% (category 2B), and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Guideline Actionable Combination Paraplatin (carboplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic large cell lung cancer, with CD274 (PD-L1) expression >/=1% - 49% (category 1) or >/= 50% (category 2B), and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung adenocarcinoma sensitive Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Guideline Actionable Combination Platinol (cisplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic lung adenocarcinoma, with CD274 (PD-L1) expression >/=1% - 49% (category 1) or >/= 50% (category 2B), and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung non-small cell carcinoma sensitive Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Guideline Actionable Combination Platinol (cisplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression >/=1% - 49% (category 1) or >/= 50% (category 2B), and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive lung large cell carcinoma sensitive Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Guideline Actionable Combination Platinol (cisplatin), Alimta (pemetrexed disodium), Imfinzi (durvalumab), and Imjudo (tremelimumab) is in guidelines as first-line therapy for patients with advanced or metastatic large cell lung cancer, with CD274 (PD-L1) expression >/=1% - 49% (category 1) or >/= 50% (category 2B), and negative for actionable molecular biomarkers (NCCN.org). detail...
CD274 positive osteosarcoma predicted - sensitive ZKAB001 Case Reports/Case Series Actionable In a Phase I/II trial, ZKAB001 treatment resulted in improved 6, 12, and 24-month event-free survival (100%) in osteosarcoma patients with CD274 (PD-L1) expression (TPS >/= 1%) compared to a 6-month EFS of 84.5% and 12 and 24-month EFS of 64.7% in patients without CD274 (PD-L1) expression (PMID: 36469563). 36469563
CD274 positive biliary tract cancer sensitive Nivolumab Phase II Actionable In a Phase II trial, baseline CD274 (PD-L1) expression was associated with increased median progression-free survival (PFS) in biliary tract cancer patients treated with Opdivo (nivolumab) compared to patients without CD274 (PD-L1) expression, with a median PFS of 19.8 months vs 2.4 months (P=0.0001) and 12-month PFS rate of 61% vs 5%, respectively (PMID: 36252287; NCT02829918). 36252287
CD274 positive esophagus squamous cell carcinoma predicted - sensitive Cisplatin + Paclitaxel + Toripalimab-tpzi Phase III Actionable In a post hoc analysis of a Phase III trial (JUPITER-06), addition of Loqtorz (toripalimab-tpzi) to paclitaxel and cisplatin improved progression-free survival (5.7 vs 5.5 mo, HR 0.59, p=0.0005 TPS H; 6.1 vs 5.7 mo, HR 0.59, p=0.0089 TPS L) and median overall survival (16.9 vs 10.8 mo, HR=0.61, p=0.0133 TPS H; not reached vs 11.6 mo, HR=0.63, p=0.0913 TPS L) in patients with esophagus squamous cell carcinoma with low (L, TPS<1%) or high (H, TPS>=1%) CD274 (PD-L1) expression (PMID: 36473145). 36473145
CD274 positive esophagus squamous cell carcinoma sensitive Capecitabine + Cisplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) and for patients with CPS <10 (category 2B) (NCCN.org). detail...
CD274 positive esophagus squamous cell carcinoma sensitive Cisplatin + Fluorouracil + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) and for patients with CPS <10 (category 2B) (NCCN.org). detail...
CD274 positive esophagus squamous cell carcinoma sensitive Fluorouracil + Oxaliplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) and for patients with CPS <10 (category 2B) (NCCN.org). detail...
CD274 positive esophagus squamous cell carcinoma sensitive Capecitabine + Oxaliplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) and for patients with CPS <10 (category 2B) (NCCN.org). detail...
CD274 positive gastroesophageal junction adenocarcinoma sensitive Fluorouracil + Nivolumab + Oxaliplatin Guideline Actionable Opdivo (nivolumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 5 (category 1) or with CPS < 5 (category 2B) (NCCN.org). detail...
CD274 positive gastroesophageal junction adenocarcinoma sensitive Capecitabine + Nivolumab + Oxaliplatin Guideline Actionable Opdivo (nivolumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin), is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 5 (category 1) or with CPS < 5 (category 2B) (NCCN.org). detail...
CD274 positive esophagus adenocarcinoma sensitive Capecitabine + Nivolumab + Oxaliplatin Guideline Actionable Opdivo (nivolumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin), is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative esophageal adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 5 (category 1) or with CPS < 5 (category 2B) (NCCN.org). detail...
CD274 positive esophagus adenocarcinoma sensitive Fluorouracil + Nivolumab + Oxaliplatin Guideline Actionable Opdivo (nivolumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression negative esophageal adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 5 (category 1) or with CPS < 5 (category 2B) (NCCN.org). detail...
CD274 positive head and neck squamous cell carcinoma no benefit Ipilimumab + Nivolumab Ipilimumab + Nivolumab Phase III Actionable In a Phase III trial (CheckMate 651), first-line Opdivo (nivolumab) plus Yervoy (ipilimumab) treatment did not improve overall survival (17.6 vs 14.6 mo; HR=0.78) or objective response rate (34.1 vs 36.0%) compared to EXTREME (Erbitux (cetuximab) plus Platinol (cisplatin) or Paraplatin (carboplatin) plus Adrucil (fluorouracil) followed by Erbitux (cetuximab) maintenance) in recurrent/metastatic CD274 (PD-L1)-positive (CPS>=20) head and neck squamous cell carcinoma patients (PMID: 36473143; NCT02741570). 36473143
CD274 positive lung non-small cell carcinoma predicted - sensitive Surufatinib + Toripalimab-tpzi Phase II Actionable In a Phase II trial, Surufatinib (HMPL-012) plus Loqtorz (toripalimab-tpzi) treatment resulted in an objective response rate of 57.1%, a disease control rate of 100%, a median duration of response of 8.31 months, a median progression-free survival of 9.63 months, a median overall survival (OS) that was not reached, and a 12-month OS rate of 64% in patients with CD274 (PD-L1)-positive (TPS>=1%) non-small cell lung cancer (Cancer Res (2023) 83 (8_Supplement): CT225; NCT04169672). detail...
CD274 positive lung non-small cell carcinoma predicted - sensitive AZD2936 Phase I Actionable In a Phase I trial (ARTEMIDE-01), AZD2936 treatment demonstrated acceptable safety and activity in patients with CD274 (PD-L1)-positive (TPS >/= 1%) advanced non-small cell lung cancer, with an overall response rate of 3.9% (3/76, 3 partial responses), stable disease in 39.5% (30/76), disease control rate (DCR) at 9 weeks of 43.4% (33/76), and a DCR at 27 weeks of 14.5% (11/76), with a duration of response of 2.1-6.4 mo (J Clin Oncol 41, 2023 (suppl 16; abstr 9050); NCT04995523). detail...
CD274 positive Advanced Solid Tumor predicted - sensitive PF-07257876 Phase I Actionable In a Phase I trial, PF-07257876 treatment was well tolerated in patients with PD-L1 (CD274)-positive advanced solid tumors and resulted in an objective response rate of 5.6% (1/18, 1 partial response in a patient with head and neck squamous cell carcinoma) (J Clin Oncol 41, 2023 (suppl 16; abstr 2529); NCT04881045). detail...
CD274 positive Advanced Solid Tumor predicted - sensitive KN046 Phase I Actionable In a Phase I trial, KN046 treatment was well tolerated and resulted in an objective response rate of 12.5% (11/88; all partial responses) and median duration of response of 16.6 months in patients with advanced solid tumors, patients with CD274 (PD-L1)-positive tumors experienced longer median progression-free survival (2.5 vs 1.3 months, p=0.0098) and overall survival (19.9 vs 5.4 months, p=0.014) than those with CD274 (PD-L1)-negative tumors ( (PMID: 37263673; NCT03733951). 37263673
CD274 positive ovary epithelial cancer no benefit Atezolizumab + Bevacizumab + Carboplatin + Pegylated liposomal doxorubicin Phase III Actionable In a Phase III trial (ATALANTE/ENGOT-ov29), Avastin (bevacizumab) combined with platinum-based chemotherapy (carboplatin plus gemcitabine, doxil, or paclitaxel) plus Tecentriq (atezolizumab) vs placebo did not meet the primary progression-free survival (PFS) objective in CD274 (PD-L1)-positive epithelial ovarian cancer patients, with a median PFS of 15.2 vs 13.1 mo (HR=0.86, P=0.30), and resulted in a median overall survival of 40.7 vs 33.6 mo (HR=0.90), respectively (PMID: 37643382; NCT02891824). 37643382
CD274 positive lung non-small cell carcinoma predicted - sensitive Atezolizumab + Tiragolumab Phase I Actionable In a Phase Ia/Ib trial (GO30103), treatment with the combination of Tecentriq (atezolizumab) and Tiragolumab (MTIG7192A) demonstrated safety and efficacy in patients with CD274 (PD-L1)-positive (>/=1%) immunotherapy-naive metastatic non-small cell lung cancer, resulting in an objective response rate of 46% (6/13, 2 complete and 4 partial responses), a disease control rate of 77% (10/13), and a duration of response of 24.2 months (PMID: 37768658; NCT02794571). 37768658
CD274 positive renal cell carcinoma predicted - sensitive Nivolumab Phase II Actionable In a Phase II trial (HCRN GU16-260), Opdivo (nivolumab) treatment in patients with CD274 (PD-L1)-positive treatment-naive advanced clear cell renal cell carcinoma resulted in an objective response rate (ORR) 50% (8/16) in patients with CD274 (PD-L1) expression between 1% to 20% and an ORR of 75% (6/8), median progression-free survival (PFS) of 20.6 months, and 1-year PFS rate of 75% in patients with CD274 (PD-L1) expression of 20% or higher (PMID: 35442713; NCT03117309). 35442713
CD274 positive head and neck cancer sensitive Ipilimumab + Nivolumab Ipilimumab + Nivolumab Guideline Actionable Opdivo (nivolumab) in combination with Yervoy (ipilimumab) is included in guidelines as first-line therapy (category 2B) for patients with CD274 (PD-L1)-positive (CPS >= 20) recurrent, unresectable, or metastatic non-nasopharyngeal head and neck cancer (NCCN.org). detail...
CD274 positive head and neck squamous cell carcinoma predicted - sensitive IO102-IO103 + Pembrolizumab Case Reports/Case Series Actionable In a Phase II trial, treatment with the combination of IO102-IO103 and Keytruda (pembrolizumab) demonstrated safety and resulted in a partial response in 50% (2/4, 1 confirmed partial response) in patients with squamous cell carcinoma of the head and neck with CD274 (PD-L1) expression (combined positive scores >/=20) (Ann Oncol (2023) 34 (suppl_2): S630; NCT05077709). detail...
CD274 positive endometrial cancer predicted - sensitive Carboplatin + Durvalumab + Paclitaxel Phase III Actionable In a Phase III trial (DUO-E), Imfinzi (durvalumab) plus platinum therapy (carboplatin/paclitaxel) followed by Imfinzi (durvalumab) with (n=150) or without Lynparza (olaparib) (n=170) maintenance resulted in an improved progression-free survival compared to platinum therapy + placebo followed by placebo maintenance (n=163) (HR=0.42 with olaparib, HR=0.63 without olaparib) in a subgroup of CD274 (PD-L1)-positive patients with advanced or recurrent endometrial cancer (PMID: 37864337; NCT04269200). 37864337
CD274 positive triple-receptor negative breast cancer predicted - sensitive Nab-paclitaxel + Toripalimab-tpzi Phase III Actionable In a Phase III trial (TORCHLIGHT), treatment with Loqtorz (toripalimab-tpzi) plus Abraxane (nab-paclitaxel) demonstrated safety and led to an improved median progression-free survival (mPFS) compared to nab-paclitaxel plus placebo in CD274 (PD-L1)-positive (CPS >/= 1) triple-negative breast cancer patients, with a mPFS of 8.4 vs 5.6 mo (HR=0.65, p=0.0102) and in the intention to treat population, a mPFS of 8.4 vs 6.9 mo (PMID: 38191615; NCT03777579, NCT04085276). 38191615
CD274 positive gastric adenocarcinoma sensitive Cisplatin + Fluorouracil + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with a fluoropyrimidine (Adrucil (fluorouracil) or Xeloda (capecitabine)) and platinum-containing chemotherapy (Platinol (cisplatin) or Eloxatin (oxaliplatin)) is included in guidelines as a preferred first-line therapy for patients with locally advanced, unresectable, or metastatic gastric adenocarcinoma expressing CD274 (PD-L1, CPS>/=10; category 1) or CD274 (PD-L1, CPS>/=1 and <10; category 2B) and without ERBB2 (HER2) overexpression (NCCN.org). detail...
CD274 positive gastric adenocarcinoma sensitive Capecitabine + Oxaliplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with a fluoropyrimidine (Xeloda (capecitabine) or Adrucil (fluorouracil)) and platinum-containing chemotherapy (Eloxatin (oxaliplatin) or Platinol (cisplatin)) is included in guidelines as a preferred first-line therapy for patients with locally advanced, unresectable, or metastatic gastric adenocarcinoma expressing CD274 (PD-L1, CPS>/=10; category 1) or CD274 (PD-L1, CPS>/=1 and <10; category 2B) and without ERBB2 (HER2) overexpression (NCCN.org). detail...
CD274 positive gastric adenocarcinoma sensitive Capecitabine + Cisplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with a fluoropyrimidine (Xeloda (capecitabine) or Adrucil (fluorouracil)) and platinum-containing chemotherapy (Platinol (cisplatin) or Eloxatin (oxaliplatin)) is included in guidelines as a preferred first-line therapy for patients with locally advanced, unresectable, or metastatic gastric adenocarcinoma expressing CD274 (PD-L1, CPS>/=10; category 1) or CD274 (PD-L1, CPS>/=1 and <10; category 2B) and without ERBB2 (HER2) overexpression (NCCN.org). detail...
CD274 positive gastric adenocarcinoma sensitive Fluorouracil + Oxaliplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with a fluoropyrimidine (Adrucil (fluorouracil) or Xeloda (capecitabine)) and platinum-containing chemotherapy (Eloxatin (oxaliplatin) or Platinol (cisplatin)) is included in guidelines as a preferred first-line therapy for patients with locally advanced, unresectable, or metastatic gastric adenocarcinoma expressing CD274 (PD-L1, CPS>/=10; category 1) or CD274 (PD-L1, CPS>/=1 and <10; category 2B) and without ERBB2 (HER2) overexpression (NCCN.org). detail...
CD274 positive colon cancer sensitive CTX-8371 Preclinical Actionable In a preclinical study, CTX-8371 treatment resulted in greater tumor growth inhibition than either Keytruda (pembrolizumab) or Tecentriq (atezolizumab) in a syngeneic mouse model of colon cancer expressing CD274 (PD-L1), with tumor regression in 62.5% (5/8) of the treated mouse models (PMID: 38379869). 38379869
CD274 positive melanoma sensitive CTX-8371 Preclinical Actionable In a preclinical study, CTX-8371 treatment resulted in fewer lung metastases than either Keytruda (pembrolizumab) or Tecentriq (atezolizumab) monotherapy in a syngeneic mouse model of melanoma expressing CD274 (PD-L1) (PMID: 38379869). 38379869
CD274 positive esophagus squamous cell carcinoma predicted - sensitive Cisplatin + Fluorouracil + Sugemalimab Phase III Actionable In a Phase III trial (GEMSTONE-304), treatment with Sugemalimab (CS1001) combined with chemotherapy (Platinol (cisplatin) and Adrucil (fluorouracil)) demonstrated safety in patients with esophagus squamous cell carcinoma (n=358), and in CD274 (PD-L1)-positive patients (IHC >=10%, n=154), resulted in improved median progression-free survival (7.0 vs 5.4 mo, HR=0.50) and median overall survival (15.7 vs 11.2 mo, HR=0.57) compared to the placebo plus chemotherapy cohort (n=78) (PMID: 38302715; NCT04187352). 38302715
CD274 positive esophagus adenocarcinoma sensitive Capecitabine + Cisplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression-negative esophageal adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS >/= 1 and <10 (category 2B) (NCCN.org). detail...
CD274 positive esophagus adenocarcinoma sensitive Capecitabine + Oxaliplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression-negative esophageal adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS >/= 1 and <10 (category 2B) (NCCN.org). detail...
CD274 positive esophagus adenocarcinoma sensitive Cisplatin + Fluorouracil + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Platinol (cisplatin) is included in guidelines as preferred first-line therapy for patients with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression-negative esophageal adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS >/= 1 and <10 (category 2B) (NCCN.org). detail...
CD274 positive esophagus adenocarcinoma sensitive Fluorouracil + Oxaliplatin + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with first-line chemotherapy including Adrucil (fluorouracil) and Eloxatin (oxaliplatin), is included in guidelines as preferred first-line therapy for patients with with locally advanced, recurrent, or metastatic ERBB2 (HER2) overexpression-negative esophageal adenocarcinoma expressing PD-L1 (CD274) with CPS >/= 10 (category 1) or with CPS >/= 1 and <10 (category 2B) (NCCN.org). detail...
CD274 positive vaginal carcinoma sensitive Nivolumab Guideline Actionable Opdivo (nivolumab) is included in guidelines as second-line or subsequent therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). detail...
CD274 positive vaginal carcinoma sensitive Pembrolizumab Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as preferred second-line or subsequent therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). detail...
CD274 positive vaginal carcinoma sensitive Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with Platinol (cisplatin), Taxol (paclitaxel), and Avastin (bevacizumab) is included in guidelines as preferred first-line therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). detail...
CD274 positive vaginal carcinoma sensitive Cisplatin + Paclitaxel + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with Platinol (cisplatin) and Taxol (paclitaxel) is included in guidelines as preferred first-line therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). detail...
CD274 positive vaginal carcinoma sensitive Carboplatin + Paclitaxel + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) is included in guidelines as preferred first-line therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). detail...
CD274 positive vaginal carcinoma sensitive Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with Paraplatin (carboplatin), Taxol (paclitaxel), and Avastin (bevacizumab) is included in guidelines as preferred first-line therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). detail...
CD274 positive triple-receptor negative breast cancer no benefit Atezolizumab + Carboplatin + Gemcitabine Phase III Actionable In a Phase III trial (Impassion132), the addition of Tecentriq (atezolizumab) to Xeloda (capecitabine) or Paraplatin (carboplatin) plus Gemzar (gemcitabine) treatment did not improve efficacy in early relapsing, unresectable, advanced CD274 (PD-L1)-positive triple-negative breast cancer patients, with median overall survival of 12.1 vs. 11.2 mo (HR=0.93, p=0.59), median progression-free survival of 4.2 vs. 3.6 mo, and objective response rates of 40% (61/177) vs. 28% (45/177) (PMID: 38755096; NCT03371017). 38755096
CD274 positive triple-receptor negative breast cancer no benefit Atezolizumab + Capecitabine Phase III Actionable In a Phase III trial (Impassion132), the addition of Tecentriq (atezolizumab) to Xeloda (capecitabine) or Paraplatin (carboplatin) plus Gemzar (gemcitabine) treatment did not improve efficacy in early relapsing, unresectable, advanced CD274 (PD-L1)-positive triple-negative breast cancer patients, with median overall survival of 12.1 vs. 11.2 mo (HR=0.93, p=0.59), median progression-free survival of 4.2 vs. 3.6 mo, and objective response rates of 40% (61/177) vs. 28% (45/177) (PMID: 38755096; NCT03371017). 38755096
CD274 positive lung non-small cell carcinoma predicted - sensitive Cemiplimab Phase III Actionable In a Phase III trial (EMPOWER-Lung 3), first-line Libtayo (cemiplimab) and platinum-doublet chemotherapy combination treatment (n=217) significantly improved median overall survival (23.5 vs 12.1 mo, HR=0.51, p<0.0001) and median progression-free survival (8.3 vs 5.5 mo, HR=0.48, p<0.0001) compared to chemotherapy and placebo (n=110) in patients with advanced non-small cell lung cancer with CD274 (PD-L1) expression >/= 1% and without EGFR, ALK, or ROS1 aberrations (PMID: 38820979; NCT03409614). 38820979
CD274 positive colorectal cancer predicted - sensitive IBI363 Phase I Actionable In a Phase I trial, IBI363 treatment demonstrated safety in patients with advanced or metastatic CD274 (PD-L1)-positive (CPS>=1) colorectal cancer who had failed on or were intolerant to standard therapy (n=13) and resulted in an objective response rate of 30.8% and disease control rate of 76.9% (J Clin Oncol 42, 2024 (suppl 16; abstr 2504); NCT05460767). detail...
CD274 positive oropharynx cancer predicted - sensitive Cemiplimab + ISA101b Phase II Actionable In a Phase II trial, ISA101b and Libtayo (cemiplimab) combination treatment demonstrated safety in patients with HPV16-positive oropharynx cancer and resulted in an overall response rate (ORR) that did not significantly differ from placebo plus Libtayo (cemiplimab) in the full analysis set (25.3 vs 22.9%, p=0.590), but in CD274 (PD-L1)-positive patients in the per protocol set (CPS>/=20), the ORR was significantly improved (61.9 vs 28.0%, p=0.026) (J Clin Oncol 42, 2024 (suppl 16; abstr 6003); NCT03669718). detail...
CD274 positive Advanced Solid Tumor predicted - sensitive MCLA-145 Phase I Actionable In a Phase I trial, MCLA-145 treatment demonstrated safety and activity in patients with CD274 (PD-L1)-positive advanced solid tumors (n=52), resulting in 5 partial responses (1 each in glioblastoma, sarcoma, cervical cancer, anal cancer, and gastric cancer) and a disease control rate of 37% (J Clin Oncol 42, 2024 (suppl 16; abstr 2520); NCT03922204). detail...
CD274 positive Advanced Solid Tumor predicted - sensitive MCLA-145 + Pembrolizumab Phase I Actionable In a Phase I trial, treatment with the combination of MCLA-145 and Keytruda (pembrolizumab) demonstrated safety and activity in patients with CD274 (PD-L1)-positive advanced solid tumors (n=19), resulting in 1 complete response in a patient with non-small cell lung cancer and 1 partial response in a patient with Merkel cell carcinoma, and a disease control rate of 68% (J Clin Oncol 42, 2024 (suppl 16; abstr 2520); NCT03922204). detail...
CD274 positive Advanced Solid Tumor predicted - sensitive SGN-PDL1V Phase I Actionable In a Phase I trial, SGN-PDL1V treatment demonstrated manageable safety and resulted in an objective response rate of 27.3% and a median duration of response of 7.9 months in patients with CD274-positive advanced solid tumors (n=55), including non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and esophageal cancer (Ann Oncol (2024) 35 (suppl_2): S486;NCT05208762). detail...
CD274 positive head and neck squamous cell carcinoma predicted - sensitive MK-7684A Phase II Actionable In a Phase II trial (KEYVIBE-005), MK-7684A treatment resulted in an objective response rate (ORR) of 29% (12/42), a median duration of response of 12.7 months, a median progression survival of 4.1 months, and a median overall survival of 15.5 months in patients with CD274 (PD-L1)-positive (CPS>/=1) head and neck squamous cell carcinoma, with an ORR of 21% (5/24) in patients with CPS=1-19 and an ORR of 41% with CPS>/=20 (Ann Oncol (2024) 35 (Suppl_2): S617-S618; NCT05007106). detail...
CD274 positive lung non-small cell carcinoma predicted - sensitive Durvalumab Phase II Actionable In a Phase II trial (SAVIMMUNE), Imfinzi (durvalumab) treatment demonstrated safety and resulted in an 8-week objective response rate (ORR) of 26%, and 16-week ORR of 24%, median progression-free survival of 2.3 months, median overall survival (OS) of 6.9 months, a 12-month OS rate of 40%, and a median duration of response of 11.3 months in patients with advanced CD274 (PD-L1)-positive (TPS >/=25%) non-small cell lung cancer with a performance score of 2 or 3 (Ann Oncol (2024) 35 (suppl_2): S842). detail...